DEA Defends HHC Ban Against Hemp Industry Court Challenge

The Drug Enforcement Administration is holding firm that hexahydrocannabinol — an intoxicating hemp-derived compound sold widely in states without a legal marijuana market — is a federally banned Schedule I drug, and it is urging two federal appeals courts to reject the hemp industry’s attempt to block that determination.

Two hemp companies have challenged a DEA rule, effective May 4, 2026, that gave HHC its own dedicated listing in the federal drug schedules. Alongside their petitions for review, both asked the courts to put the rule on hold while the cases proceed. In briefs filed in late June 2026, the agency argued that neither company cleared the legal bar for that kind of emergency relief, and that pausing the rule would change nothing about HHC’s status anyway.

What the agency told the courts

The DEA’s core position is that its rule was a housekeeping move, not a new prohibition. The compound, the agency says, has been illegal for years because it meets the federal definition of tetrahydrocannabinols, the broad class of THC-type substances already sitting in Schedule I. The new rule simply breaks HHC out into its own entry and assigns it a separate drug code, which lets the agency set production quotas for manufacturers that handle the compound for permitted purposes.

That framing is central to the agency’s case against a pause. “With or without the final rule, HHC is a schedule I controlled substance,” the DEA told the courts, arguing that the companies would face the same legal and commercial risk whether or not the rule is stayed. Blocking it, the agency added, would only sow confusion about the compound’s status and undercut the government’s effort to regulate it.

At the heart of the dispute is how to read the 2018 Farm Bill, which legalized hemp and its derivatives so long as they carry no more than 0.3 percent delta-9 THC by dry weight. The DEA’s view is that the carve-out covers only THC compounds found in or drawn from the cannabis plant, not those built in a lab. HHC is typically made by chemically altering CBD, a process the agency treats as synthetic production. Cannabinoids produced through chemical conversion, the agency wrote, do not qualify as hemp even when they start from hemp-derived material.

Where the companies push back

The challengers — IHC Investments, Inc., in the Ninth Circuit and Bluestar Operations, LLC, in the Fourth Circuit — say the DEA is rewriting the statute to criminalize an entire category of products Congress chose to legalize. Their petitions, filed in early June 2026, argue that lawmakers used deliberately broad language covering derivatives, extracts, cannabinoids and isomers, and never excluded compounds made through ordinary processing steps like conversion, hydrogenation or distillation.

Both companies also lean on the major questions doctrine, the principle that an agency needs clear authorization from Congress before it decides an issue of sweeping national importance. A ban on HHC, they contend, carries exactly that kind of weight, reaching a hemp market that moves billions of dollars in commerce.

Each suit is anchored in friendly circuit precedent. The Ninth Circuit ruled in 2022 that delta-8 THC products qualify as legal hemp, holding that a cannabinoid’s source, not its method of manufacture, controls its legal status. The Fourth Circuit reached a similar conclusion in 2024, finding that THC-O-acetate is lawful hemp and rejecting the DEA’s narrower reading as unpersuasive. Bluestar argues the agency cannot recast the same rule as a harmless technical fix while also claiming the company has no standing to challenge it. The agency, it says, cannot have it both ways.

David Sergi, the attorney leading the Ninth Circuit case, said the rule has already done real damage, pointing to “the immediate cancellation of contracts, loss of banking relationships, and the potential destruction of significant inventory.” He has described the two suits as a coordinated industry defense against what he calls federal overreach.

A November deadline looms over the fight

Even if the companies prevail, the reprieve could be short-lived. A spending law President Donald Trump signed in late 2025 narrows the federal definition of hemp on November 12, 2026, capping legal products at 0.4 milligrams of total THC per container. That threshold would sweep up HHC and other intoxicating synthetics regardless of how the court battles end, unless Congress changes the language or delays it, an outcome some lawmakers and even the White House have pushed for.

For now, hemp businesses are left with the same uncertainty the litigation was meant to settle. The DEA has signaled it intends to act more aggressively against unregulated cannabinoid products, federal regulators have missed their own deadlines for guidance on the coming hemp limits, and neither court has set a date for argument.